Singapore, Feb. 4 -- Australia-based startup AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, has entered into a Collaboration and Exclusive Licensing Agreement with Canadian startup 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need, reflecting AdvanCell's strategy to build a durable pipeline of differentiated targeted alpha therapies addressing large oncology markets.

The collaboration brings together 48Hour Discovery's peptide discovery platform and AdvanCell's 212Pb expertise to rapidly construct and advance a peptide-based radiotherapeutic program. Leverag...